Biomarin Pharmaceutical Inc(BMRN) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 27 at 7:59 PM ET (Korea 10/28 08:59)
Full metrics table
| Index | - | P/E | 149.23 | EPS (ttm) | 0.37 | Insider Own | 1.29% | Shs Outstand | 193.5M | Perf Week | -1.93% |
| Market Cap | 10.71B | Forward P/E | 8.62 | EPS next Y | 81.81% | Insider Trans | -0.83% | Shs Float | 191.1M | Perf Month | -6.91% |
| Enterprise Value | 14.06B | PEG | 0.14 | EPS next Q | -0.08 | Inst Own | 102.26% | Short Float | 6.31% | Perf Quarter | -9.81% |
| Income | 0.07B | P/S | 3.1 | EPS this Y | 96.26% | Inst Trans | 1.28% | Short Ratio | 5.45 | Perf Half Y | 3.85% |
| Sales | 3.46B | P/B | 1.69 | EPS next 5Y | 61.71% | ROA | 0.76% | Short Interest | 12.05M | Perf YTD | -6.87% |
| Book/sh | 32.66 | P/C | 12.26 | EPS past 3/5Y | 34.05% -16.79% | ROE | 1.18% | 52W High | -22.02% ($70.98) | Perf Year | 5.09% |
| Cash/sh | 4.52 | P/FCF | 14.51 | Sales past 3/5Y | 16.55% 11.97% | ROIC | 0.74% | 52W Low | 12.36% ($49.26) | Perf 3Y | -31.39% |
| Dividend Est. | - | EV/EBITDA | 17.74 | EPS Y/Y TTM | -89.03% | Gross Margin | 73.93% | Volatility(W/M) | 2.96% 2.74% | Perf 5Y | -22.82% |
| Dividend TTM | - | EV/Sales | 4.07 | Sales Y/Y TTM | 13.69% | Oper. Margin | 18.5% | ATR (14) | 1.61 | Perf 10Y | -31.68% |
| Dividend Ex-Date | - | Quick Ratio | 1.32 | EPS Q/Q | -81.28% | Profit Margin | 2.11% | RSI (14) | 39.8 | Recom | 1.55 |
| Dividend Gr. 3/5Y | - | Current Ratio | 2.39 | Sales Q/Q | 20.41% | SMA20 | -1.15% ($55.99) | Beta | 0.21 | Target Price | $91.62 |
| Payout | - | Debt/Eq | 0.67 | Earnings | 2026/11/2 | SMA50 | -9.64% ($61.25) | Rel Volume | 1.11 | Prev Close | $55.75 |
| Employees | 3221 | LT Debt/Eq | 0.56 | EPS/Sales Surpr. | 26.66% 6.19% | SMA200 | -5.26% ($58.42) | Avg Volume(3M) | 2.21M | Price | $55.35 |
| IPO | 1999/7/23 | Option/Short | Yes/Yes | Trades | 19795 | Volume | 2,463,192 | Change | -0.72% |
A U.S. biopharmaceutical company that develops and sells treatments for rare genetic diseases, specializing in rare disease therapeutics. Because the patient population is small, drug prices tend to be high, and both sales of marketed products and pipeline performance drive earnings results.
Over the past 1 year, roughly in the middle
22% below its 1-year high.
Traded about as much as usual. That is 111% of its average volume.
Next earnings report: November 2
5 days to go.
BMRN has a sound balance sheet but weak earning power
After all costs, only $2.11 of every $100 in sales is left.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +96.3% this year.
Tap to view numbers
The price is about the industry average
Counting its debt, for $100 of yearly operating cash you would pay $1,774. Peers typically go for $2,408. Compared with its own 5-year average, it is 48% pricier now.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
The outlook is positive
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -22.8%. The S&P 500 did +70% over the same period.
Tap to view numbers
No dividend
It reinvests profits in the business instead of paying dividends.
Ownership looks stable
Institutions hold 102.3%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #21 of 594 in the industry
Based on market cap of $11B.
TECH#20 Bio-Techne Corp $11B PER 62.7 BMRN#21 Biomarin Pharmaceutical Inc $11B PER 149.2 
TWST#22 Twist Bioscience Corp $11B PER - 
MDGL#23 Madrigal Pharmaceuticals Inc $10B PER - 
KYMR#24 Kymera Therapeutics Inc $10B PER - 
FAQ
What kind of company is BMRN?
BMRN belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of BMRN?
The market cap of BMRN is approximately $10.7B, ranking 881 within its sector.
What is the P/E ratio of BMRN?
BMRN has a P/E ratio of approximately 149.2x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for BMRN?
BMRN has recorded a 52-week high of $70.98 and a low of $49.26.
